Screener
Xeris Biopharma Holdings, Inc. XERS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Assets | June 30, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Other accrued liabilities | 39,706 | 33,155 |
| Accrued trade discounts and rebates | 46,858 | 43,253 |
| Accrued returns reserve | 18,598 | 18,969 |
| Other current liabilities | 4,976 | 4,889 |
| Total current liabilities | 189,568 | 109,574 |
| Long-term debt, net of unamortized debt issuance costs | 188,807 | 220,335 |
| Non-current operating lease liabilities | 30,542 | 31,531 |
| Other liabilities | 12,722 | 8,398 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s accrued expenses?
- Xeris Biopharma Holdings, Inc. (XERS) reported accrued expenses of $4.98M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s accrued expenses changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s accrued expenses increased by 204.7% year-over-year, from $1.63M to $4.98M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s accrued expenses has grown at a 72.3% compound annual growth rate (CAGR), from $322K to $4.89M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Xeris Biopharma Holdings, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude